A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Clinical trial NCT05375903 · COMPLETED

Trial details

NCT number: NCT05375903
Sponsor: UroGen Pharma Ltd.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Non-muscle Invasive Bladder Cancer NMIBC Carcinoma in Situ of Bladder Bladder Cancer Urothelial Carcinoma Bladder Urothelial Carcinoma Recurrent

Start date: 2022-06-01
Primary completion: 2026-01-09
Enrollment: 51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.